» Articles » PMID: 31545459

Metastatic Renal Cell Carcinoma Cells Growing in 3D on Poly‑D‑lysine or Laminin Present a Stem‑like Phenotype and Drug Resistance

Overview
Journal Oncol Rep
Specialty Oncology
Date 2019 Sep 24
PMID 31545459
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

3D spheroids are built by heterogeneous cell types in different proliferative and metabolic states and are enriched in cancer stem cells. The main aim of the study was to investigate the usefulness of a novel metastatic renal cell carcinoma (RCC) 3D spheroid culture for in vitro cancer stem cell physiology research and drug toxicity screening. RCC cell lines, Caki‑1 (skin metastasis derived) and ACHN (pleural effusion derived), were efficiently cultured in growth‑factor/serum deprived, defined, StemXvivo and Nutristem medium on laminin‑coated or poly‑D‑lysine‑coated plates. In optimal 3D culture conditions, ACHN cells (StemXVivo/poly‑D‑lysine) formed small spheroids with remaining adherent cells of an epithelial phenotype, while Caki‑1 cells (StemXVivo/laminin) formed large dark spheroids with significantly reduced cell viability in the center. In the 3D structures, expression levels of genes encoding stem transcription factors (OCT4, SOX2, NES) and RCC stem cell markers (CD105, CD133) were deregulated in comparison to these expression levels in traditional 2D culture. Sunitinib, epirubicin and doxycycline were more toxic to cells cultured in monolayers than for cells in 3D spheroids. High numbers of cells arrested in the G0/G1 phase of the cell cycle were found in spheroids under sunitinib treatment. We showed that metastatic RCC 3D spheroids supported with ECM are a useful model to determine the cancer cell growth characteristics that are not found in adherent 2D cultures. Due to the more complex architecture, spheroids may mimic in vivo micrometastases and may be more appropriate to investigate novel drug candidate responses, including the direct effects of tyrosine kinase inhibitor activity against RCC cells.

Citing Articles

Characterisation of 3D Bioprinted Human Breast Cancer Model for In Vitro Drug and Metabolic Targeting.

Danko T, Petovari G, Raffay R, Sztankovics D, Moldvai D, Vetlenyi E Int J Mol Sci. 2022; 23(13).

PMID: 35806452 PMC: 9267600. DOI: 10.3390/ijms23137444.


Advances in Renal Cell Carcinoma Drug Resistance Models.

Xiang Y, Zheng G, Zhong J, Sheng J, Qin H Front Oncol. 2022; 12:870396.

PMID: 35619895 PMC: 9128023. DOI: 10.3389/fonc.2022.870396.


Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.

Rausch M, Rutz A, Allard P, Delucinge-Vivier C, Docquier M, Dormond O Int J Mol Sci. 2021; 22(12).

PMID: 34208775 PMC: 8235637. DOI: 10.3390/ijms22126467.


Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Zhao Y, Zheng X, Zheng Y, Chen Y, Fei W, Wang F Front Oncol. 2021; 11:650453.

PMID: 33968752 PMC: 8100244. DOI: 10.3389/fonc.2021.650453.


The Role of Biomimetic Hypoxia on Cancer Cell Behaviour in 3D Models: A Systematic Review.

Liu Y, Mohri Z, Alsheikh W, Cheema U Cancers (Basel). 2021; 13(6).

PMID: 33809554 PMC: 7999912. DOI: 10.3390/cancers13061334.


References
1.
Yuan Z, Mo J, Zhao G, Shu G, Fu H, Zhao W . Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells. Front Pharmacol. 2016; 7:423. PMC: 5103413. DOI: 10.3389/fphar.2016.00423. View

2.
Morrison R, Schleicher S, Sun Y, Niermann K, Kim S, Spratt D . Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2010; 2011:941876. PMC: 2958340. DOI: 10.1155/2011/941876. View

3.
Covello K, Kehler J, Yu H, Gordan J, Arsham A, Hu C . HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 2006; 20(5):557-70. PMC: 1410808. DOI: 10.1101/gad.1399906. View

4.
Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y . p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015; 6:e1637. PMC: 4669810. DOI: 10.1038/cddis.2015.2. View

5.
Gotink K, Broxterman H, Labots M, de Haas R, Dekker H, Honeywell R . Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011; 17(23):7337-46. PMC: 4461037. DOI: 10.1158/1078-0432.CCR-11-1667. View